Author: Ken Dropiewski

Heartflow Files Patent Infringement Lawsuit Against Cleerly

Financial by 0 comments

Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow PlatformMOUNTAIN VIEW, Calif., April 13, 2026 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that it has filed a patent infringement lawsuit against Cleerly, Inc. in the United States District Court for the Eastern District of Texas. The complaint seeks permanent injunctive relief and damages arising from Cleerly’s unauthorized and continued use of Heartflow’s patented technology. Heartflow asserts that Cleerly’s Ischemia, Plaque Analysis, and Compare products infringe six of Heartflow’s patents with priority dates from 2012 to 2018, protecting Heartflow innovations developed years before the introduction of any Cleerly product. The filed complaint can be accessed on Heartflow’s website here. “Heartflow pioneered a significant medical technology that has touched over 600,000 patients’ lives. Our team has worked tirelessly since 2010 to develop the Heartflow Platform, a first-of-its-kind AI solution that has been used to detect and manage coronary artery disease,” said John Farquhar, CEO of Heartflow. “We take seriously our responsibility to protect the intellectual property that supports this field and the clinicians and patients it serves.” Heartflow maintains a robust intellectual property portfolio comprising over 600 granted patent assets worldwide. The Company remains focused on advancing its platform and expanding access to precise, non-invasive cardiovascular care. About Heartflow’s Technology and ResearchHeartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,800 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by ACC/AHA guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 600,000 patients worldwide.1 Key benefits include: Proprietary data pipeline: Built from more than 160 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001. About Heartflow, Inc.Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com. Media ContactElliot Levyelevy@heartflow.com Investor ContactNick Laudiconlaudico@heartflow.com _______________________ 1 Gulati, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. J Am Coll Cardiol.

Continue Reading →

Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting

Peripheral/Endo Radiology by 0 comments

Successful Execution of the Limited Market Release (LMR) Includes Adoption by Globally Recognized Healthcare Systems in the U.S. Market and Demonstrates Broad Market Scalability in Key Endovascular ProceduresHINGHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that it has successfully executed its limited market release (LMR) and will commence its full market release (FMR) in the U.S. as planned. To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their networks, including globally recognized hospitals such as Emory Healthcare and Tampa General Hospital. Microbot considers this achievement a reflection of the highly effective execution of the LIBERTY System’s LMR and positions the Company to commence the FMR of the LIBERTY System as originally planned, at the Society of Interventional Radiology (SIR) Annual Scientific Meeting, being held in Toronto, ON, Canada, from April 11-15. The LIBERTY system is creating an entirely new category as the only FDA-cleared, single-use, remotely operated robotic system. It has been successfully used commercially across a variety of procedures, including Prostate Artery Embolization (PAE), Uterine Fibroid Embolization (UFE), Genicular Artery Embolization (GAE), Y90 mapping, Y90 deliveries, and peripheral arterial interventions. Physicians have highlighted LIBERTY’s precision, short learning curve, fast setup, the ability to use their preferred wires and catheters, as well as the potential to improve efficiency by reducing procedure time and number of instruments used to perform such procedures. In preparation for the FMR, the Company has further enhanced its commercial team core capabilities by adding salespeople in key locations and broadening its sales footprint from four to eight sales territories, with a goal of having 12 territories across the U.S. by the end of 2026. “We successfully achieved our goals for the limited market release of the LIBERTY System, including its adoption by leading hospitals across multiple peripheral procedures, giving us the momentum to commence, as planned, the full market release at the SIR conference,” commented Harel Gadot, Chairman, President & CEO. “It’s exciting to see the level of enthusiasm among our existing customers, first when they initially use LIBERTY, utilizing it across multiple procedures, and then as they expand it to other hospital sites within their network. The variety of case types shows the system’s flexibility, and its ease of use is generating high customer satisfaction. I also believe the level of customer adoption during the limited market release in such a short time further demonstrates a shorter sales cycle compared to traditional surgical robots, which is another key differentiator and one we believe will lead to accelerated adoption.” SIR represents over 8,000 practicing interventional radiology physicians, trainees, medical students, scientists, and clinical associates. This will be the first opportunity for the Company to showcase the LIBERTY system at the conference, which features its primary addressable U.S. target market. SIR, along with the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) have recently adopted new guidelines, which were published in CardioVascular and Interventional Radiology (CVIR), and endorsed by at least eight other medical societies. These guidelines cover updated evidence, address new exposure sources such as CT-guided procedures and radioembolization, and radiation protection during pregnancy for female practitioners, as well as addresses musculoskeletal risks for interventional radiology staff. This follows a recent American Medical Association (AMA) policy adopted late last year to strengthen protections for health care professionals from occupational exposure to ionizing radiation. “This year’s SIR conference is a pivotal moment for Microbot Medical, and the timing of the conference represents an optimal opportunity for our team to leverage the market feedback to commence the full market release of the LIBERTY System,” added Mr. Gadot. “Our targeted end users will be in attendance, and we plan to engage with them directly, enhancing our opportunities over the coming months as we broaden our presence in existing territories and expand into new ones.” The Company plans to meet with physicians and other stakeholders, to showcase the LIBERTY system at booth #423, and to further educate physicians on the system’s full capabilities to accelerate market adoption in the U.S. LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. It is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain, addressing key clinical and operational challenges faced by interventional radiology teams. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care. Learn more at www.microbotmedical.com and connect on LinkedIn and X. Safe Harbor Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law. Contacts: IR@microbotmedical.comMedia@microbotmedical.com

Continue Reading →

Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio

Financial by 0 comments

Portage, Michigan, April 13, 2026 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK), a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease. The acquisition will strengthen Stryker’s Peripheral Vascular (PV) portfolio by adding revascularization technology. Once cleared for use in applicable markets, the product will complement Stryker’s existing PV offerings and support the company’s strategy to expand its presence in arterial disease treatment. “This acquisition represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs,” said Kevin Lobo, Chair and CEO, Stryker. “Combining this innovation with Stryker’s scale and clinical expertise, we believe we can help expand treatment options for physicians and improve care for patients with calcified peripheral arterial disease.” AVS’ technology is designed to use pulsed CO₂-generated pressure waves uniformly delivered through an IVL balloon catheter, to fracture calcium and optimize luminal gain. The platform is designed to enhance catheter deliverability, treatment speed and therapy efficiency. IVL is a fast-growing technology in cardiovascular intervention and is used to treat calcified peripheral and coronary lesions. It is expected to experience strong growth as physicians adopt IVL-based calcium modification in complex procedures. This transaction is subject to customary closing conditions. Stryker and AVS will continue to operate as separate entities and proceed with business as usual until the transaction closes. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com. About Amplitude Vascular Systems (AVS) Amplitude Vascular Systems (AVS) is a medical device company based in Boston, Mass., focused on treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital, Cue Growth Partners, and others. It was founded in 2017 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at the University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. More information is available at www.avspulse.com. Contacts For investor inquiries:Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com For media inquiries:Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com

Continue Reading →

CVRx Reports Preliminary First Quarter 2026 Financial Results

Financial by 0 comments

Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior authorizations managed by our market access teamFirst site activated in BENEFIT-HF clinical trial MINNEAPOLIS, April 13, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited first quarter 2026 financial and operating results. “The investments we made in our team and programs in 2025 are beginning to pay off, allowing us to deliver strong revenue growth in the first quarter,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “We are also starting to observe positive effects from the Category I CPT Code that took effect at the beginning of the year, as early data shows improved 30-day prior authorization approval rates compared to what we saw in 2025. Our continued progress in reducing the barriers to adoption for Barostim have enabled us to start the year off with positive momentum, and we are excited about what that means for the balance of 2026 and beyond.” First Quarter 2026 Total revenue for the first quarter of 2026 is expected to be in the range of $14.7 million to $14.8 million compared to revenue for the first quarter of 2025 of $12.3 million, representing growth of approximately 20%. Gross margin for the first quarter of 2026 is expected to be approximately 87% compared to 84% in the first quarter of 2025. Total operating expenses for the first quarter of 2026 are expected to be approximately $25 million compared to $23.7 million in the first quarter of 2025. As of March 31, 2026, the Company had a total of 257 U.S. active implanting centers, as compared to 252 as of December 31, 2025. The number of sales territories in the U.S. increased by three to a total of 56 during the three months ended March 31, 2026. As of March 31, 2026, cash and cash equivalents were approximately $72.3 million. Reimbursement Update As previously disclosed, the Category I Current Procedural Terminology (CPT) codes for baroreflex activation therapy using the Company’s Barostim device replaced Category III codes as of Jan. 1, 2026, which eliminates the automatic denials regularly seen with Category III codes and improves prior authorization predictability to fairly pay physicians for the procedure. Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior authorizations managed by the Company’s in-house market access team, which has increased from 31% in 2024 to 44% in 2025 and to 50% for the first two months of 2026. First Site Activated in BENEFIT-HF Clinical Trial On March 31, 2026, the first site was activated in the BENEFIT-HF trial and enrollment is expected to begin in the second quarter of 2026. This trial, as previously disclosed, is a landmark randomized controlled trial designed to evaluate Barostim’s impact on all-cause mortality and heart failure decompensation events in an expanded population of heart failure patients with left ventricular ejection fractions up to 50% and NT-proBNP levels up to 5,000 pg/mL. If successful, the BENEFIT-HF trial could expand the indicated patient population for Barostim approximately three times, significantly broadening access to this proven neuromodulation-based approach to heart failure management. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including statements regarding our future financial performance, our anticipated growth strategies (including statements regarding the expected timing, enrollment, scope and outcomes of the BENEFIT-HF clinical trial), anticipated trends in our industry, our business prospects and our opportunities. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “outlook,” “guidance,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this press release are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history of significant losses, which we expect to continue; our limited history operating as a commercial company and our dependence on a single product, Barostim; our limited commercial sales experience marketing and selling Barostim; our ability to continue demonstrating to physicians and patients the merits of our Barostim; any failure by third-party payors to provide adequate coverage and reimbursement for the use of Barostim; our competitors’ success in developing and marketing products that are safer, more effective, less costly, easier to use or otherwise more attractive than Barostim; any failure to receive access to hospitals; our dependence upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide; the constant growth and development of technology, including artificial intelligence; product liability claims; future lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and ultimately unsuccessful; any failure to retain our key executives or recruit and hire new employees; impacts on adoption and regulatory approvals resulting from additional long-term clinical data about our product, including those resulting from the BENEFIT-HF clinical trial; and other important factors that could cause actual results, performance or achievements to differ materially from those that are found in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Preliminary First Quarter 2026 Results This press release includes estimated financial results for the first quarter of 2026, which are preliminary, unaudited and represent the most recent current information available to Company management. The Company’s actual results may differ from these estimated financial results, including due to the completion of its financial closing procedures and final adjustments. The Company expects to issue full financial results for the first quarter of 2026 in mid-May. Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@cvrx.com Media Contact:Emily MeyersCVRx, Inc.763-416-2853emeyers@cvrx.com

Continue Reading →

Catheter Precision Announces Accepted Publication in Leading European Medical Journal

Rhythm by 0 comments

Clinical Evidence Further Demonstrates Efficacy and Accuracy of VIVO for Ventricular ProceduresFORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”) today announced that the results of a recently concluded VIVO study have been accepted in EP Europace, the leading European electrophysiology journal. The EP Europace journal provides an avenue of communication for top-quality European and international original, scientific work and reviews in the fields of arrhythmias, pacing and cellular electrophysiology. The journal offers readers a collection of contemporary, original, peer-reviewed papers, invited papers and editorial comments, together with book reviews and correspondence. The accepted manuscript titled “Accuracy of a non-invasive electrocardiographic imaging system in scar-dependent ventricular tachycardia: Relationship to arrhythmogenic substrate and imaging defined scar” highlights the feasibility of VIVO for scar-related ventricular tachycardia (VT) was led by Professor Tarv Dhanjal, MBChB(hons) PhD FRCP FESC FEHRA, Professor of Cardiology (University of Warwick). This study included 31 patients and mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems to determine accuracy. The study concluded that ECGi mapping with VIVO can accurately predict the arrhythmogenic substrate for scar-dependent VT and incorporation of ECGi mapping to conventional VT ablation workflows may improve procedural efficiency. Of additional importance, this study compares VIVO’s predictability of epicardial VTs to a four step ECG based algorithm. In patients with Non-ischemic cardiomyopathy (NICM), the VIVO localization had a 100% specificity and 66.7% sensitivity, while a traditional four-step ECG-based algorithm had a sensitivity and specificity of 50% and 0%, further demonstrating VIVO’s capabilities to improve procedural workflow.David Jenkins, CEO of Catheter Precision, says, “This study demonstrates that VIVO works in a wide range of patients, including those with scar related ventricular tachycardia and that it can improve procedural workflow and reduce procedure time even in very difficult procedures like epicardial VT. We are very pleased with the outcomes of this study and plan to start a larger, multi-center study later this year to prove out these results on a larger scale.”   About VIVO™  Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark. About Catheter PrecisionCatheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements. CONTACTS: Investor Relations973-691-2000IR@catheterprecision.com #   #   #

Continue Reading →

Bracco Affirms ASNC Position Statement Elevating Cardiac PET with Myocardial Blood Flow as Preferred Standard for Coronary Artery Disease

Coronary/Structural Heart by 0 comments

Guidance validates the comprehensive approach Bracco has advanced for more than three decades NEEDHAM, Mass., April 13, 2026 /PRNewswire/ — Bracco, the market leader in diagnostic imaging and the pioneer in cardiac positron emission tomography (PET) for more than three decades, today…

Continue Reading →

TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

Radiology by 0 comments

WESTMINSTER, Colo.–(BUSINESS WIRE)–TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada. TriSalus will showcase new clinical a

Continue Reading →

Kestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner

Financial by 0 comments

KIRKLAND, Wash., April 09, 2026 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced it has been named a 2026 USA TODAY Top Workplaces award winner. “Being named a USA TODAY Top Workplace highlights a team dedicated to a meaningful purpose and mission with a commitment to making a real difference for patients and clinicians,” said Brian Webster, President and CEO of Kestra Medical Technologies. “The opportunity to collaborate with people who share that responsibility creates strong alignment, defines our culture, and empowers our teams to work together to develop innovative, life-saving technologies and services. That’s what makes this recognition so impactful—it comes directly from our team and reflects their belief in what we’re building and pride in the culture we’ve created.” This recognition is based on confidential team member feedback collected through a research-backed Energage survey, measuring key drivers of engagement, alignment, and organizational performance. “Earning a USA TODAY Top Workplaces award reflects an organization’s credibility and commitment to its people,” said Eric Rubino, CEO of Energage. “Because it is based on team member feedback, it shows that people believe in the organization and its leadership. That trust is what sets companies apart.” About EnergageMaking the world a better place to work together.™Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 20 years of culture research and the results from 30 million employees surveyed across more than 80,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit energage.com or topworkplaces.com. About KestraKestra Medical Technologies is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. CONTACT: Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com

Continue Reading →

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development

Financial by 0 comments

Idorsia thanks Alberto Gimona – most recently Head of Global Clinical Development and Medical Affairs – and wishes him all the best for a well-deserved retirementAmer Joseph joins Idorsia as EVP, Chief Medical Officer & Head of Global Clinical Development, becoming a member of the Idorsia Executive Committee Allschwil, Switzerland – April 9, 2026Idorsia Ltd (SIX: IDIA) announces the appointment of Dr Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) & Head of Global Clinical Development, effective May 1, 2026. He succeeds Dr Alberto Gimona, who is retiring. Amer is an accomplished clinical development leader with a strong track record of delivering regulatory filings, executing mid‑ and late‑stage global clinical development programs, building high‑performing teams, and driving operational excellence with clarity, discipline and speed. His leadership – rooted in scientific rigor, curiosity, and a strong sense of ownership – reflects Idorsia’s culture of innovation, agility, and purposeful execution. As CMO & Head of Global Clinical Development, Amer will lead global clinical strategy and execution across all therapeutic areas, as well as ensure medical governance, helping to advance Idorsia’s pipeline and shape the company’s scientific and medical direction. Jean-Paul Clozel, MD, Chairman and interim CEO of Idorsia commented:“I’m delighted to welcome Amer to Idorsia. His breadth of clinical development experience, passion for advancing science, collaborative leadership style, and energetic, open approach make him an outstanding addition to our organization. Amer brings exactly the vision, discipline, and patient-focused mindset we need as we sharpen our scientific priorities and accelerate progress on our most promising assets. I’m confident he will strengthen our ability to deliver meaningful medicines to patients.” Amer Joseph, MD, commented:“I am truly excited to be joining Idorsia. The company has a remarkable scientific legacy, a strong culture of innovation, and a broad pipeline with real potential to make a difference in the lives of millions of patients. I look forward to working with the leadership team, and the talented teams across the company to advance our medicines with scientific rigor and a deep sense of purpose.” Thanking Alberto GimonaIdorsia extends its heartfelt gratitude to Dr. Alberto Gimona, who retires after years of dedicated service and leadership at Idorsia, most recently as Head of Global Clinical Development and Medical Affairs. Alberto has played a pivotal role in building and guiding Idorsia’s development capabilities and advancing key clinical programs. The company thanks him warmly for his invaluable contributions and wishes him the very best for his retirement. Jean-Paul concluded:“I also want to sincerely thank Alberto for his leadership, dedication, and unwavering commitment to science throughout his years at Idorsia. He has supported our assets and our teams over many years and leaves an amazing legacy of drugs that have made a real difference to so many people over his career. We wish him a very happy and fulfilling retirement.” About Dr Amer JosephAmer joins Idorsia from Chiesi Group, where he most recently served as Vice President, Head of Global Clinical Development, leading a global organization spanning clinical development, clinical operations, biometrics, real-world evidence, and digital health. He delivered late‑stage development programs in respiratory, neonatology, cardiovascular and rare diseases, launched three products in 2023, and drove multiple FDA and EMA approvals. Previously, Amer spent over nine years at Bayer, holding global leadership roles in cardiology and nephrology. He played a pivotal role in developing the blockbuster cardio-renal franchise finerenone, leading Phase 2 and Phase 3 programs involving 13,000 patients across 48 countries and steering global health authority interactions. He also gained rare disease experience at GSK, providing clinical leadership for programs in transthyretin amyloidosis. Amer began his career as a clinician in the United Kingdom, working in leading London hospitals including the London Chest Hospital, St Bartholomew’s, and the Royal London Hospital. He has a deep expertise across the heart-kidney-metabolic axis, strong engagement with global and US key opinion leaders, and considerable experience collaborating with commercial and medical affairs to shape differentiated clinical strategies. He has authored over 40 peer‑reviewed publications in top‑tier journals such as NEJM, JAMA, Circulation, European Heart Journal, and JACC, and has contributed to numerous due diligences and business development processes across rare disease, cardiovascular and renal assets. Notes to the editor About IdorsiaThe purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “intend”, “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Attachment

Press Release PDF

Continue Reading →

First Implant of KingstronBio’s ProStyle M® Transcatheter Mitral Valve System Successfully Completed in National Multicenter Confirmatory Study

Coronary/Structural Heart by 0 comments

SHANGHAI, April 9, 2026 /PRNewswire/ — On March 12, 2026, the first implant of the ProStyle M® Transcatheter Mitral Valve System (ProStyle M®) was successfully completed under pure ultrasound guidance as part of its confirmatory clinical study. The device is independently developed by…

Continue Reading →
1 … 7 8 9 10 11 … 1,329